Get the Stockscreener App
16.88
1.02%
0.17
After Hours:
16.88
Bausch Lomb Corp stock is traded at $16.88, with a volume of 232.58K.
It is up +1.02% in the last 24 hours and up +4.20% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$16.71
Open:
$16.78
24h Volume:
232.58K
Relative Volume:
0.58
Market Cap:
$6.02B
Revenue:
$5.10B
Net Income/Loss:
$-352.00M
P/E Ratio:
-16.57
EPS:
-1.0189
Net Cash Flow:
$-66.14M
1W Performance:
+2.06%
1M Performance:
+4.20%
6M Performance:
+12.76%
1Y Performance:
+41.49%
1-Day Range:
$16.70
$16.91
1-Week Range:
$16.14
$16.99
52-Week Range:
$10.45
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.88 | 5.96B | 5.10B | -352.00M | -66.14M | -1.0189 |
ISRG
Intuitive Surgical Inc
|
468.36 | 165.94B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
155.52 | 44.30B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
80.73 | 38.96B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
47.93 | 38.69B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
228.80 | 33.61B | 5.40B | 1.49B | 1.78B | 10.12 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Bausch & Lomb Legal Chief Sees Pay Dip To $3.6M In 2025 - Law360
Bausch + Lomb Corp. Opens with a 5.46% Gain, Outperforming S&P 500 - Markets Mojo
BLCO SEC FilingsBausch + Lomb Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] Bausch & Lomb Corp SEC Filing - Stock Titan
Bausch + Lomb (NYSE: BLCO) seeks approval to expand equity plan and elect board - Stock Titan
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb Corporation Receives FDA 510(k) Clearance For Bi-Blade+ Dual-Port Vitrectomy Cutter And Adaptive Fluidics Advanced Update - marketscreener.com
Bausch + Lomb Corp stock: Eye health innovation drives undervaluation debate - AD HOC NEWS
Bausch + Lomb receives FDA clearance for surgical device - Investing.com
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update - Business Wire
Bausch Lomb (NYSE:BLCO) Eye Health Story Gains Attention On Nyse Composite Today - Kalkine Media
Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $16.34 - 富途牛牛
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
A Look At Bausch + Lomb (NYSE:BLCO) Valuation As ASCRS Presentations Highlight Eye Health Portfolio - simplywall.st
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe - Business Wire
BLCO: Evercore ISI Group Adjusts Price Target While Maintaining Rating | BLCO Stock News - GuruFocus
Evercore Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Cuts Target Price to $17 - 富途牛牛
Bausch + Lomb Corporation (BLCO) stock price, news, quote and history - Yahoo Finance Singapore
Dry eye and cataract data lead Bausch + Lomb's 45-study ASCRS lineup - Stock Titan
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & SuppliesSpecialty Stocks - Yahoo! Finance Canada
BLCO Stock Price, Quote & Chart | BAUSCH + LOMB CORP (NYSE:BLCO) - ChartMill
Bausch + Lomb Corporation (NYSE:BLCO) Receives Average Rating of "Hold" from Analysts - MarketBeat
Should Positive ELIOS Glaucoma Trial Results Require Action From Bausch + Lomb (BLCO) Investors? - simplywall.st
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29 - Yahoo Finance
Bausch + Lomb Corp Stock: Eye Health Leader with Strong Product Portfolio and Growth Potential for I - AD HOC NEWS
Tudor Investment Corp ET AL Takes $2.25 Million Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
A Look At Bausch + Lomb (BLCO) Valuation After Recent Share Price Pullback - Yahoo Finance
Bausch And Lomb (NYSE:BLCO) Shares Draw Eyes Across Nyse Composite Today - Kalkine Media
3 Reasons BLCO is Risky and 1 Stock to Buy Instead - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - The Motley Fool
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $19 - 富途牛牛
Bausch + Lomb Achieves Key Milestone in Glaucoma Treatment with ELIOS System - Intellectia AI
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma - BioSpace
Bausch + Lomb reports positive glaucoma trial results for ELIOS - Investing.com
Glaucoma laser left 82% of patients medication-free in U.S. trial - Stock Titan
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Market Shifts and Deb - AD HOC NEWS
RBC reiterates Bausch & Lomb stock rating on DED rival delay - Investing.com Australia
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
RBC reiterates Bausch & Lomb stock rating on DED rival delay By Investing.com - Investing.com South Africa
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Slowdown and D - AD HOC NEWS
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position - AOL.com
Bausch + Lomb Corporation (NYSE:BLCO) Sees Large Decline in Short Interest - MarketBeat
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Shifts - AD HOC NEWS
Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness - Yahoo Finance
Bausch + Lomb Corporation $BLCO Shares Purchased by Compass Rose Asset Management LP - MarketBeat
Bausch + Lomb Corporation Investigated by the Portnoy Law Firm - GlobeNewswire
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):